FRANKFURT, April 25 (Reuters) - Boehringer Ingelheim, Germany's second-largest drugmaker, posted a gain in operating income of 20.7 percent to 3.5 billion euros ($4.27 billion) last year, boosted by the purchase of Sanofi's veterinary medicine.


20


Reuters

19 Related Articles from 2018-04-25